These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 38686320)

  • 21. Bacterial and eukaryotic extracellular vesicles and nonalcoholic fatty liver disease: new players in the gut-liver axis?
    Villard A; Boursier J; Andriantsitohaina R
    Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G485-G495. PubMed ID: 33471632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases.
    Bruneau A; Hundertmark J; Guillot A; Tacke F
    Front Med (Lausanne); 2021; 8():725390. PubMed ID: 34650994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The gut-liver axis: how the gut promotes liver disease].
    Demir M; Tacke F
    Inn Med (Heidelb); 2022 Oct; 63(10):1028-1035. PubMed ID: 36053302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies.
    Jayachandran M; Qu S
    Rev Endocr Metab Disord; 2023 Dec; 24(6):1189-1204. PubMed ID: 37840104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis.
    Yao N; Yang Y; Li X; Wang Y; Guo R; Wang X; Li J; Xie Z; Li B; Cui W
    Front Nutr; 2022; 9():906511. PubMed ID: 35782947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
    Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
    World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Role of gut-liver-immune axis in the pathogenesis of nonalcoholic steatohepatitis].
    Shao L; Song Y; Shi JP
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):505-509. PubMed ID: 34225424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver.
    Ko M; Kamimura K; Owaki T; Nagoya T; Sakai N; Nagayama I; Niwa Y; Shibata O; Oda C; Morita S; Kimura A; Inoue R; Setsu T; Sakamaki A; Yokoo T; Terai S
    Dis Model Mech; 2021 Mar; 14(3):. PubMed ID: 33787507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications.
    Fang J; Yu CH; Li XJ; Yao JM; Fang ZY; Yoon SH; Yu WY
    Front Cell Infect Microbiol; 2022; 12():997018. PubMed ID: 36425787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis.
    Quesada-Vázquez S; Aragonès G; Del Bas JM; Escoté X
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of plant natural products on metabolic-associated fatty liver disease and the underlying mechanisms: a narrative review with a focus on the modulation of the gut microbiota.
    Cai T; Song X; Xu X; Dong L; Liang S; Xin M; Huang Y; Zhu L; Li T; Wang X; Fang Y; Xu Z; Wang C; Wang M; Li J; Zheng Y; Sun W; Li L
    Front Cell Infect Microbiol; 2024; 14():1323261. PubMed ID: 38444539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The contribution of the gut-liver axis to the immune signaling pathway of NAFLD.
    Liu J; Wu A; Cai J; She ZG; Li H
    Front Immunol; 2022; 13():968799. PubMed ID: 36119048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Demonstration of Gut-Barrier Dysfunction in Early Stages of Non-alcoholic Fatty Liver Disease: A Proof-Of-Concept Study.
    Kaushal K; Agarwal S; Sharma S; Goswami P; Singh N; Sachdev V; Poudel S; Das P; Yadav R; Kumar D; Pandey G; Gunjan D; Saraya A
    J Clin Exp Hepatol; 2022; 12(4):1102-1113. PubMed ID: 35814507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential mechanisms linking gut microbiota and portal hypertension.
    Baffy G
    Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents.
    Tokuhara D
    Front Nutr; 2021; 8():700058. PubMed ID: 34250000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement.
    Ji Y; Yin Y; Sun L; Zhang W
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role and effective therapeutic target of gut microbiota in NAFLD/NASH.
    Liu Q; Liu S; Chen L; Zhao Z; Du S; Dong Q; Xin Y; Xuan S
    Exp Ther Med; 2019 Sep; 18(3):1935-1944. PubMed ID: 31410156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ginsenoside Rh4 Improves Hepatic Lipid Metabolism and Inflammation in a Model of NAFLD by Targeting the Gut Liver Axis and Modulating the FXR Signaling Pathway.
    Yang S; Duan Z; Zhang S; Fan C; Zhu C; Fu R; Ma X; Fan D
    Foods; 2023 Jun; 12(13):. PubMed ID: 37444230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.